CCT 137690
CCT 137690 is a potent and orally available aurora kinase inhibitor with IC50s of 15, 25, and 19 nM for aurora A, B and C, respectively.
Product Specifications
CAS Number
1095382-05-0
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Aurora Kinase
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/CCT-137690.html
Purity
99.54
Solubility
DMSO : 16.67 mg/mL (ultrasonic)
Smiles
CC1=CC(CN(CC2)CCN2C3=C4C(NC(C5=CC=C(N6CCN(C)CC6)C=C5)=N4)=NC=C3Br)=NO1
Molecular Formula
C26H31BrN8O
Molecular Weight
551.48
Precautions
H302, H315, H319, H335
References & Citations
[1]Bavetsias V, et al. Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. J Med Chem. 2010 Jul 22;53 (14) :5213-28.|[2]Faisal A, et al. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Mol Cancer Ther. 2011 Nov;10 (11) :2115-23.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Aurora A; Aurora B; Aurora C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LC426137 20 µg
LINC02877 (NM_001101337) Human Over-expression Lysate
Sign In for Pricing
View Details 